SAN DIEGO, March 9, 2021 /PRNewswire/ -- Viriom Inc., a San Diego CA-based biotech and Chromis, a joint venture of the ChemRar Group and the Russian Direct Investment Fund (RDIF) reported a summary of the multicenter, open-labeled, efficacy and safety study of Avifavir (favipiravir) in patients with COVID-19 at the Conference on Retroviruses and Opportunistic Infections CROI2021.
Viriom and Chromis have reported that data from a study of directly acting antiviral drug, Avifavir (favipiravir) demonstrated reduced time to virus elimination in Covid-19 patients.
SAN DIEGO, Feb. 2, 2021 /PRNewswire/ -- Viriom Inc (Viriom) announces that its antiviral drug Elpida®(elsulfavirine) has been included in the preferred first-line antiretroviral therapy (ART) regimens by the Ministry of Health of the Russian Federation according to updated clinical guidelines for the treatment of HIV infection in adults and children. Regimens for adults include the combination of elsulfavirine + lamivudine (or emtricitabine) + tenofovir. Viriom has filed for the market authorization of the fixed dose combination of elsulfavirine + tenofovir and emtricitabine in Russia and the Eurasian Economic Union.
Viriom announced the initiation of a phase 2a study investigating the efficacy of an intramuscular long-acting injectable nanoformulation of VM1500A in HIV-infected patients.